268 related articles for article (PubMed ID: 22480319)
1. Impact of safety-related regulatory action on clinical practice: a systematic review.
Piening S; Haaijer-Ruskamp FM; de Vries JT; van der Elst ME; de Graeff PA; Straus SM; Mol PG
Drug Saf; 2012 May; 35(5):373-85. PubMed ID: 22480319
[TBL] [Abstract][Full Text] [Related]
2. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
3. Effect of safety issues with HIV drugs on the approval process of other drugs in the same class: an analysis of European Public Assessment Reports.
Arnardottir AH; Haaijer-Ruskamp FM; Straus SM; de Graeff PA; Mol PG
Drug Saf; 2011 Nov; 34(11):1101-14. PubMed ID: 21981437
[TBL] [Abstract][Full Text] [Related]
4. The impact of direct healthcare professional communication on prescribing practice in the UK hospital setting: an interrupted time series analysis.
Thomas SK; Hodson J; McIlroy G; Dhami A; Coleman JJ
Drug Saf; 2013 Jul; 36(7):557-64. PubMed ID: 23657825
[TBL] [Abstract][Full Text] [Related]
5. Safety-related regulatory actions for orphan drugs in the US and EU: a cohort study.
Heemstra HE; Giezen TJ; Mantel-Teeuwisse AK; de Vrueh RL; Leufkens HG
Drug Saf; 2010 Feb; 33(2):127-37. PubMed ID: 20082539
[TBL] [Abstract][Full Text] [Related]
6. Safety-related regulatory actions for biologicals approved in the United States and the European Union.
Giezen TJ; Mantel-Teeuwisse AK; Straus SM; Schellekens H; Leufkens HG; Egberts AC
JAMA; 2008 Oct; 300(16):1887-96. PubMed ID: 18940975
[TBL] [Abstract][Full Text] [Related]
7. Do drug-related safety warnings have the expected impact on drug therapy? A systematic review.
Georgi U; Lämmel J; Datzmann T; Schmitt J; Deckert S
Pharmacoepidemiol Drug Saf; 2020 Mar; 29(3):229-251. PubMed ID: 32045502
[TBL] [Abstract][Full Text] [Related]
8. Measuring the impact of medicines regulatory interventions - Systematic review and methodological considerations.
Goedecke T; Morales DR; Pacurariu A; Kurz X
Br J Clin Pharmacol; 2018 Mar; 84(3):419-433. PubMed ID: 29105853
[TBL] [Abstract][Full Text] [Related]
9. Timing of new black box warnings and withdrawals for prescription medications.
Lasser KE; Allen PD; Woolhandler SJ; Himmelstein DU; Wolfe SM; Bor DH
JAMA; 2002 May; 287(17):2215-20. PubMed ID: 11980521
[TBL] [Abstract][Full Text] [Related]
10. The impact of wording in "Dear doctor" letters and in black box labels.
Weatherby LB; Nordstrom BL; Fife D; Walker AM
Clin Pharmacol Ther; 2002 Dec; 72(6):735-42. PubMed ID: 12496755
[TBL] [Abstract][Full Text] [Related]
11. Implementation of warnings from Dear Doctor Letters (Rote-Hand-Briefe): an analysis of medication data from a large cohort of elderly patients.
Schächtele S; Tümena T; Gaßmann KG; Fromm MF; Maas R
Dtsch Arztebl Int; 2014 Apr; 111(15):255-63. PubMed ID: 24776610
[TBL] [Abstract][Full Text] [Related]
12. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
[TBL] [Abstract][Full Text] [Related]
13. Printed educational materials: effects on professional practice and healthcare outcomes.
Giguère A; Zomahoun HTV; Carmichael PH; Uwizeye CB; Légaré F; Grimshaw JM; Gagnon MP; Auguste DU; Massougbodji J
Cochrane Database Syst Rev; 2020 Jul; 8(8):CD004398. PubMed ID: 32748975
[TBL] [Abstract][Full Text] [Related]
14. Contraindicated medications dispensed with cisapride: temporal trends in relation to the sending of 'Dear Doctor' letters.
Weatherby LB; Walker AM; Fife D; Vervaet P; Klausner MA
Pharmacoepidemiol Drug Saf; 2001 May; 10(3):211-8. PubMed ID: 11501334
[TBL] [Abstract][Full Text] [Related]
15. A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009.
Mol PG; Straus SM; Piening S; de Vries JT; de Graeff PA; Haaijer-Ruskamp FM
Drug Saf; 2010 Jun; 33(6):463-74. PubMed ID: 20486729
[TBL] [Abstract][Full Text] [Related]
16. Promoting and supporting self-management for adults living in the community with physical chronic illness: A systematic review of the effectiveness and meaningfulness of the patient-practitioner encounter.
Rees S; Williams A
JBI Libr Syst Rev; 2009; 7(13):492-582. PubMed ID: 27819974
[TBL] [Abstract][Full Text] [Related]
17. The effect of financial incentives on the quality of health care provided by primary care physicians.
Scott A; Sivey P; Ait Ouakrim D; Willenberg L; Naccarella L; Furler J; Young D
Cochrane Database Syst Rev; 2011 Sep; (9):CD008451. PubMed ID: 21901722
[TBL] [Abstract][Full Text] [Related]
18. Impact of regulatory guidances and drug regulation on risk minimization interventions in drug safety: a systematic review.
Nkeng L; Cloutier AM; Craig C; Lelorier J; Moride Y
Drug Saf; 2012 Jul; 35(7):535-46. PubMed ID: 22702638
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
